Please provide your email address to receive an email when new articles are posted on . Longer screening intervals of 3 to 5 years may be acceptable in certain circumstances, including those with type ...

Please provide your email address to receive an email when new articles are posted on . Ford Medical will distribute AEYE-DS to U.S. pharmacies and non-acute centers. The system pairs with a retinal ...

Despite its underutilization, AI-powered diabetic retinopathy screening was associated with greater OCT referral rates than traditional screening methods. Artificial intelligence (AI)-based diabetic ...

In a real-world setting, artificial intelligence (AI) proved to be effective in screening for referable diabetic retinopathy. Using artificial intelligence (AI) in real-world settings is an effective ...

Recent reports suggest diabetic retinopathy is more common in younger people than previously thought, leading to a call for more frequent screening for this condition and more attention to follow-up ...

AI-based retinal imaging and diagnostics startup AEYE Health announced today it received clearance from the FDA to market its diagnostic screening system for diabetic retinopathy. There are 35 million ...

Compared with human graders, AI algorithms’ classification of real-world images shows similar accuracy for detecting any, or referable, diabetic retinopathy. Artificial intelligence (AI) screening ...

Some hospitals are finding it difficult to scale AI across their enterprise — with this process often complicated by things like inadequate technology infrastructures, varying needs across specialties ...

Reducing the frequency of eye screening in patients with diabetes from annually to every other year would delay detection of sight-threatening diabetic retinopathy (STDR) and proliferative diabetic ...

One-third of diabetic adults in the U.S. do not receive annual eye exams. Additionally, lack of pupillary dilation before exams is associated with ungradable, or insufficient exams. In September 2022, ...

SECAUCUS, N.J., April 4, 2022 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced a collaboration with IRIS (Intelligent ...